keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis, ustekinumab, biologics

keyword
https://www.readbyqxmd.com/read/28329588/ustekinumab-for-treatment-of-cutaneous-crohn-s-disease
#1
Rana Abdat, Alina Markova, Francis A Farraye, Michael K Lichtman
Cutaneous Crohn disease (CD) affecting the vulva, perineum, and perianal skin, is a rare entity, which may accompany or precede gastrointestinal CD. Vulvar involvement, if untreated, may ultimately require extensive surgery including vulvectomy to gain control of the disease. Both gastrointestinal and cutaneous CD respond to biologics, which block TNF. In addition, ustekinumab, which targets both IL-12 and IL-23 cytokines, is effective in patients with gastrointestinal CD who fail TNF blockade. However, it is unclear if ustekinumab is effective for cutaneous CD...
October 15, 2016: Dermatology Online Journal
https://www.readbyqxmd.com/read/28301617/patient-preference-for-dosing-frequency-based-on-prior-biologic-experience
#2
Mingliang Zhang, Chureen Carter, William H Olson, Michael P Johnson, Susan K Brennem, Seina Lee, Kamyar Farahi
BACKGROUND: There is limited research exploring patient preferences regarding dosing frequency of biologic treatment of psoriasis. METHODS: Patients with moderate-to-severe plaque psoriasis identified in a healthcare claims database completed a survey regarding experience with psoriasis treatments and preferred dosing frequency. Survey questions regarding preferences were posed in two ways: (1) by likelihood of choosing once per week or 2 weeks, or 12 weeks; and (2) by choosing one option among once every 1-2 or 3-4 weeks or 1-2 or 2-3 months...
March 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28300862/reversible-posterior-leukoencephalopathy-syndrome-rpls-in-a-psoriasis-patient-treated-with-ustekinumab
#3
Lauren Dickson, Alan Menter
The use of monoclonal antibodies against interleukin (IL)-12 and -23, such as ustekinumab, has considerably reduced the disease burden in many patients with moderate to severe psoriasis. Reversible posterior leukoencephalopathy syndrome (RPLS) is a neurologic disorder that has been documented with increased frequency with the use of systemic and biologic agents. We report a case of a 58-year-old man with psoriasis who presented with confusion and memory difficulties after being on treatment with ustekinumab for over six years...
February 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28273375/characteristics-of-patient-receiving-ustekinumab-compared-with-secukinumab-for-treatment-of-moderate-to-severe-plaque-psoriasis-nationwide-results-from-the-dermbio-registry
#4
A Egeberg, L Iversen, R Gniadecki, L Hvid, T N Dam, L E Bryld, L Skov
BACKGROUND: While safety and efficacy of ustekinumab and secukinumab, monoclonal antibodies approved for psoriasis, are described in clinical trials, data on their real-life application are lacking. OBJECTIVE: We compared the characteristics of patients initiating first-time treatment with secukinumab or ustekinumab. METHODS: All Danish patients with moderate-to-severe plaque psoriasis treated with biologics are recorded in the nationwide DERMBIO registry...
March 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28240404/etanercept-adalimumab-and-ustekinumab-in-psoriasis-analysis-of-209-treatment-series-in-austria
#5
Leo Richter, Igor Vujic, Alma Sesti, Babak Monshi, Martina Sanlorenzo, Christian Posch, Klemens Rappersberger
BACKGROUND AND OBJECTIVES: Widely used in the treatment of psoriasis, biologics have been tested in numerous clinical trials. However, drug efficacies and adverse events (AEs) may differ in 'real-world' patients as they do not undergo as rigorous selection and monitoring. Our objective was to examine drug survival, efficacy, and AEs (quality, time of onset) in 'real-world' psoriasis patients treated with etanercept, adalimumab, and ustekinumab. PATIENTS AND METHODS: Retrospective data analysis (Jan 1, 2004 to Jun 30, 2015) of patients treated at a psoriasis clinic in an Austrian hospital...
March 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28230450/characteristics-and-medication-use-of-psoriasis-patients-who-may-or-may-not-qualify-for-randomized-controlled-trials
#6
William Malatestinic, Beth Nordstrom, Jashin J Wu, Orin Goldblum, Kathleen Solotkin, Chen-Yen Lin, Kristin Kistler, Kathy Fraeman, Joseph Johnston, Lcdr Lesley Hawley, Nicholas Sicignano, Andre Araujo
BACKGROUND: Clinical trials impose exclusion criteria that may limit the generalizability of results. OBJECTIVES: To (a) determine the percentage of real-world patients who would qualify for psoriasis randomized controlled trials; (b) ascertain differences between moderate-to-severe psoriasis patients who would be eligible, ineligible, or potentially eligible for clinical trials; and (c) compare their biologic treatment patterns. METHODS: Moderate-to-severe psoriasis patients were identified from the U...
March 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28224166/routine-laboratory-parameter-dynamics-and-laboratory-adverse-events-in-psoriasis-patients-on-long-term-treatment-with-adalimumab-etanercept-and-ustekinumab
#7
Jochen H Hoffmann, Christian Knoop, Alexander H Enk, Eva N Hadaschik
Only limited data on laboratory parameter dynamics and safety under prolonged biologic treatment in a "real-world" scenario are available for recommendations on screening and monitoring. This study is a retrospective analysis of routine parameter dynamics and laboratory adverse events (LAE) in psoriasis patients on long-term treatment (n = 199) with tumour necrosis factor (TNF)-α-antagonists (adalimumab, etanercept), and the interleukin (IL)12/23-antagonist ustekinumab. Overall, neutrophil (PMN) counts (-11%) and triglycerides (+9%) changed considerably...
February 22, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28162025/secukinumab-in-the-treatment-of-psoriasis-an-update
#8
Radomir Reszke, Jacek C Szepietowski
Biological drugs are pharmaceuticals manufactured using biotechnology methods that may target specific cytokines, cytokine receptors or surface molecules, and modulate the immunological response of the organism. Psoriasis is a common cutaneous disease in which biological drugs have been evaluated and widely accepted in clinical practice. Secukinumab is a monoclonal antibody targeting IL-17A which has been extensively researched in clinical trials and registered in treating moderate to severe plaque psoriasis...
March 2017: Immunotherapy
https://www.readbyqxmd.com/read/28150333/varicella-zoster-virus-meningitis-under-ustekinumab-because-of-plaque-psoriasis
#9
Claudia Stöllberger, Josef Finsterer
Ustekinumab, a monoclonal antibody that binds to the shared p40 subunit of interleukin (IL)-12 and IL-23, is approved in the USA and Europe for moderate to severe plaque psoriasis. There are concerns that biologic treatments like ustekinumab may lead to an increased rate of infections. We report a 77-year-old woman who developed varicella zoster virus meningitis 8 weeks after initiation of ustekinumab therapy because of plaque psoriasis. She presented clinically with sudden onset of fatigue, vertigo, nausea and epileptic seizures...
February 2, 2017: Journal of Dermatology
https://www.readbyqxmd.com/read/28139054/ustekinumab-for-the-treatment-of-acrodermatitis-continua-of-hallopeau-refractory-to-anti-tnf-agents
#10
Esra Adışen, İlkay Özer, Berkay Temel, Mehmet Ali Gürer
Acrodermatitis continua of Hallopeau (ACH) is a variant of pustular psoriasis that is often very difficult to treat. Almost all anti-psoriatic agents have been used in the treatment of ACH. Ustekinumab, a fully human monoclonal antibody of the IgG1 class, is directed to the shared p40 subunit of cytokines IL-12 and IL-23. Herein, we present our experience of ustekinumab use in a 50-year-old man who was resistant to anti-tumor necrosis factor-α agents. Though initial therapy with ustekinumab achieved a sustained response in our patient, after a seven months of interruption, retreatment resulted in a slower and poorer response than the initial regimen...
January 30, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28094756/treatment-modifying-factors-of-biologics-for-psoriatic-arthritis-a-systematic-review-and-bayesian-meta-regression
#11
REVIEW
Eric Druyts, Jacqueline B Palmer, Chakrapani Balijepalli, Keith Chan, Mir Sohail Fazeli, Vivian Herrera, Jeroen P Jansen, Jay J H Park, Steve Kanters, Andreas Reimold
OBJECTIVES: The aim of this study was to explore factors that modify treatment effects of non-conventional biologics versus placebo in patients with psoriatic arthritis. METHODS: A systematic literature review and meta-regression was conducted. The biologics included etanercept, infliximab, adalimumab, golimumab, certolizumab, ustekinumab, tocilizumab, anakinra, abatacept, rituximab, and secukinumab. Outcomes included American College of Rheumatology (ACR) 20 and 50, Psoriasis Area Severity Index (PASI) 75, and 36-Item Short Form Health Survey (SF-36) Physical and Mental Component Summaries (PCS and MCS)...
January 15, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28092212/systemic-medications-used-in-treatment-of-common-dermatological-conditions-safety-profile-with-respect-to-pregnancy-breast-feeding-and-content-in-seminal-fluid
#12
S M Brown, K A Aljefri, R Waas, P J Hampton
Prescribing for pregnant or lactating patients and male patients wishing to father children can be a difficult area for dermatologists. There is a lack of review articles of commonly used systemic medications in dermatology with respect to their effects on developing embryogenesis and their potential transfer across the placenta, in breast milk and in seminal fluid. This paper aims to provide an up to date summary of evidence to better equip dermatologists to inform patients about the effects of systemic medications commonly used in dermatology to treat conditions such as atopic dermatitis, psoriasis and acne, on current and future embryogenesis and fertility...
January 16, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28071837/use-of-tnf-inhibitors-and-ustekinumab-for-psoriasis-during-pregnancy-a-patient-series
#13
Tamara Lund, Simon Francis Thomsen
From 2002 to 2016 a total of seven women with severe refractory psoriasis were exposed to the TNF-inhibitors infliximab and adalimumab or to the IL12/23 inhibitor ustekinumab during one or more pregnancies. Maternal, fetal or teratogenic toxicity were not detected during pregnancy and puerperium. All pregnancies were uneventful and resulted in delivery of 10 healthy children in total, one of the women is due February 2017. Postpartum, five of the women were lactating, but none of the women or newborns developed adverse reactions...
January 10, 2017: Dermatologic Therapy
https://www.readbyqxmd.com/read/28042732/the-potential-utility-of-tildrakizumab-an-interleukin-23-inhibitor-for-the-treatment-of-psoriasis
#14
REVIEW
Zenas Z N Yiu, Richard B Warren
The approved biologic therapies are effective for the treatment of psoriasis, but have limitations. Tildrakizumab has a different mechanism of action and is a humanized immunoglobulin G1κ that binds to the p19 subunit of IL23. Areas covered: Phase I, II and III clinical trials investigated the pharmacokinetics, efficacy, safety and immunogenicity of tildrakizumab for patients with psoriasis. The mean half-life of tildrakizumab is between 20.2 to 28.2 days. Tildrakizumab achieved a PASI 75 of 66% and 74% at week 16 for the doses of 100 mg and 200 mg respectively in a phase IIb randomised clinical trial (RCT), and PASI 75 of 61%/64% and 62%/66% at week 12 for 100 mg and 200 mg respectively in two phase III RCTs...
February 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28042711/the-impact-of-pasi-75-and-pasi-90-on-quality-of-life-in-moderate-to-severe-psoriasis-patients
#15
Michael Abrouk, M Nakamura, T H Zhu, B Farahnik, J Koo, T Bhutani
BACKGROUND: It is well known that psoriasis significantly impacts patients' quality of life (QoL). With the introduction of improved treatment modalities with biologic agents, more patients with moderate to severe psoriasis are able to achieve better results as measured by the Psoriasis Area and Severity Index (PASI). PASI 75 indicates a 75% or greater reduction in PASI scores from baseline and is indicative of excellent disease improvement. With newer biologic agents such as secukinumab, ixekizumab and brodalumab, patients are now capable of achieving PASI 90, introducing additional clinical decisions for physicians when considering treatment options...
January 18, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28038888/biologic-drug-survival-in-israeli-psoriasis-patients
#16
Guy Shalom, Arnon D Cohen, Michael Ziv, Cohen Barak Eran, Ilan Feldhamer, Tamar Freud, Eitan Berman, Shirley Oren, Emmilia Hodak, Lev Pavlovsky
BACKGROUND: Drug survival is defined as the time period of treatment with a certain drug until its cessation. The role of previous exposure to traditional systemic treatments in biologic survival is still unknown. OBJECTIVE: To investigate the drug survival rates of biologic treatments in patients with psoriasis and to identify predictor factors. METHODS: Survival analysis was performed on patients with severe psoriasis who received adalimumab, infliximab, etanercept, and ustekinumab for treatment of psoriasis, drawn from the Clalit Health Services database...
December 28, 2016: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28026823/anti%C3%A2-cytokine-therapy-for-psoriasis-not-only-tnf%C3%A2-%C3%AE-blockers-overview-of-reports-on-the-effectiveness-of-therapy-with-il%C3%A2-12-il%C3%A2-23-and-t-and-b-lymphocyte-inhibitors
#17
Dominika Wcisło-Dziadecka, Martyna Zbiciak, Ligia Brzezińska-Wcisło, Urszula Mazurek
TNF‑α inhibitors - infliximab, etanercept and adalimumab - can be used in the treatment of psoriasis vulgaris and psoriatic arthritis, along with other inhibitors of proinflammatory cytokines, such as interleukin‑12 (IL‑12) and IL‑23. This paper presents the results of research on the use of biological drugs other than the tumor necrosis factor blockers (TNF‑α), namely inhibitors of IL‑12 and IL‑23 (ustekinumab), T‑cell inhibitors (alefacept and efalizumab), B‑cell inhibitors (rituximab), anti‑IL‑17 agents (secukinumab, ixekizumab, and brodalumab) and IL23p19 inhibitors (guselkumab and tildrakizumab)...
December 8, 2016: Postȩpy Higieny i Medycyny Doświadczalnej
https://www.readbyqxmd.com/read/27976465/determination-of-the-nail-psoriasis-severity-index-improvement-rate-standards-for-nail-psoriasis-treatment-in-a-phase-iv-clinical-trial-of-ustekinumab-the-marcopolo-study
#18
LETTER
S W Youn, B R Kim, S Cho, S J Seo, E S Lee, J Y Roh, G S Choi, M G Lee
No abstract text is available yet for this article.
December 15, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27879076/drug-survival-rates-and-reasons-for-drug-discontinuation-in-psoriasis
#19
Tobias Arnold, Marthe-Lisa Schaarschmidt, Raphael Herr, Joachim E Fischer, Sergij Goerdt, Wiebke K Peitsch
BACKGROUND AND OBJECTIVES: Moderate-to-severe psoriasis frequently requires long-term systemic therapy. Reflecting efficacy, safety, and treatment satisfaction, drug survival is an indicator of therapeutic success. The objective of the present study was to assess drug survival rates and reasons for discontinuation of fumaric acid esters (FAE), methotrexate (MTX), acitretin (ACI), cyclosporine A (CyA), adalimumab (ADA), etanercept (ETA), infliximab (INF), and ustekinumab (UST) in patients with moderate-to-severe psoriasis...
November 2016: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/27864841/clinical-factors-predicting-the-therapeutic-response-to-ustekinumab-in-patients-with-moderate-to-severe-chronic-plaque-psoriasis
#20
Young Ji Hwang, Sang Woong Youn, Bo Ri Kim, Dae Young Yu, Youngdoe Kim, Antonio Pires, Soyun Cho, Seong Jun Seo, Eun So Lee, Joo Young Roh, Gwang Seong Choi, Min Geol Lee
While ustekinumab has been widely used as an effective biologic for the treatment of chronic plaque psoriasis, no prospective studies have specifically investigated the clinical factors that may influence treatment outcomes with ustekinumab. This post-hoc analysis aimed to identify specific clinical factors that may influence treatment outcomes with ustekinumab in psoriasis patients. In the MARCOPOLO study, 102 Korean patients with moderate to severe psoriasis were analyzed to assess the influence of baseline characteristics as clinical factors on clinical response (improvement in Psoriasis Area and Severity Index by ≥75%/90% [PASI75/PASI90]) to ustekinumab...
November 18, 2016: Journal of Dermatology
keyword
keyword
77975
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"